Effect of GLP-1 receptor agonist in combination with insulin on abdominal fat in patients with type 2 diabetes trial
- Conditions
- Patients with type 2 diabetes
- Registration Number
- JPRN-UMIN000015867
- Lead Sponsor
- Tokyo Medical and Dental University
- Brief Summary
iraglutide treatment significantly reduced visceral fat area (VFA) at 24 weeks; whereas, subcutaneous fat are (SFA) was unchanged. albuminuria, liver attenuation index, and CRP levels were significantly reduced by liraglutide at 24 weeks and there was no difference in skeletal muscle index between the two groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
Type 1 diabetes Patients with allergy to incretin mimetics Patients with interstitial pneumonia Patints with liver chirrosis or renal failure Patients who had experienced acute coronary syndrome or stroke or acute pancreatitis within 3 months prior to enrollment Patients with malignant neoplasms Patients who are alread treated with DPP4 inhibitors and/or GLP-1 receptor agonists. Patients whose dosage of insulin has been changed by > 20 % within 3 months prior to enrollment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in visceral fat area 24 after administration of liraglutide
- Secondary Outcome Measures
Name Time Method The change in liver attenuation index 24 after administration of liraglutide